Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Accumulated Expenses (2016 - 2026)

Corvus Pharmaceuticals' Accumulated Expenses history spans 12 years, with the latest figure at $7.0 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 80.44% to $7.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Mar 2026, up 80.44% year-over-year, with the annual reading at $6.5 million for FY2025, 690.98% up from the prior year.
  • Accumulated Expenses came in at $7.0 million for Q1 2026, up from $6.5 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $8.6 million in Q3 2022 to a low of $658000.0 in Q1 2023.
  • The 5-year median for Accumulated Expenses is $4.2 million (2024), against an average of $4.0 million.
  • Year-over-year, Accumulated Expenses plummeted 91.24% in 2023 and then surged 690.98% in 2025.
  • Corvus Pharmaceuticals' Accumulated Expenses stood at $7.5 million in 2022, then plummeted by 90.94% to $684000.0 in 2023, then grew by 19.88% to $820000.0 in 2024, then soared by 690.98% to $6.5 million in 2025, then grew by 7.69% to $7.0 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Accumulated Expenses are $7.0 million (Q1 2026), $6.5 million (Q4 2025), and $5.7 million (Q3 2025).